Last updated: August 1, 2026
Sitavig is a prescription 50 mg mucoadhesive buccal tablet containing acyclovir for episodic treatment of recurrent herpes labialis, commonly called cold sores. The FDA approved Sitavig in 2013 through NDA 204426. Its clinical differentiation is local delivery through the upper gum, allowing a single dose at the first sign of symptoms instead of the repeated oral dosing required for conventional acyclovir tablets.[1]
Sitavig has limited clinical-development activity because its pivotal efficacy program is complete and the product is already approved. Its commercial opportunity remains constrained by generic acyclovir, low-cost OTC topical products, limited physician switching incentives and uncertain current distribution. The principal business value lies in differentiated delivery, adherence and convenience rather than in a new antiviral mechanism.
What is Sitavig and how does the drug work?
Sitavig contains acyclovir, a nucleoside analogue that inhibits herpes simplex virus DNA polymerase after intracellular phosphorylation. The tablet adheres to the buccal mucosa near the upper canine tooth and releases acyclovir locally over several hours.
The FDA indication is narrow:
| Attribute |
Sitavig |
| Active ingredient |
Acyclovir |
| Strength |
50 mg |
| Dosage form |
Mucoadhesive buccal tablet |
| Administration |
One tablet applied to the upper gum |
| Indication |
Recurrent herpes labialis in immunocompetent adults |
| Treatment timing |
At the earliest symptom, such as tingling or itching |
| FDA approval |
2013 |
| Application |
NDA 204426 |
| Drug class |
Antiviral |
| Reference treatment alternatives |
Oral acyclovir, valacyclovir, famciclovir, topical agents |
The product is not a long-acting systemic formulation. Its value proposition is local mucosal residence and single-dose administration.
What clinical trials supported Sitavig approval?
Sitavig’s approval was supported by randomized clinical studies in adults with recurrent herpes labialis. The pivotal program evaluated a single 50 mg buccal dose applied at the earliest symptom and compared outcomes with placebo.
The FDA labeling reported a reduction in healing time and lesion duration in treated patients. The treatment was most effective when used during the prodromal phase, before vesicle formation.[1]
What were the main Sitavig clinical outcomes?
The principal clinical findings reported in the FDA label included:
- Shorter time to healing of the cold-sore lesion.
- Shorter duration of lesion symptoms.
- Reduction in the progression of lesions in some treated patients.
- A safety profile consistent with local buccal administration and acyclovir exposure.
The pivotal studies did not establish superiority over oral valacyclovir or famciclovir. Their comparator was placebo, which limits the strength of direct comparative claims against established antiviral regimens.
What adverse events were associated with Sitavig?
The most prominent treatment-related issue is local application-site discomfort. The prescribing information identifies local irritation and related oral adverse effects among the clinically relevant risks.[1]
Sitavig is contraindicated in patients with hypersensitivity to acyclovir, valacyclovir or formulation components. The label also warns about potential renal toxicity associated with systemic acyclovir exposure, although Sitavig is administered as a single low-dose buccal product.
Are there active Sitavig clinical trials?
Sitavig does not appear to have an active late-stage clinical-development program in the public record available through June 2024. The clinical package is mature, and the drug’s commercial question is market access rather than regulatory validation.
No established development program has been publicly associated with:
- Pediatric expansion.
- Genital herpes treatment.
- Herpes zoster treatment.
- Immunocompromised-patient use.
- Combination therapy.
- New strengths or extended-release versions.
The absence of a visible expansion program reduces near-term clinical-trial costs but also limits the possibility of creating new indications that could support additional market exclusivity.
What is the FDA regulatory status of Sitavig?
Sitavig received FDA approval in 2013 under NDA 204426. The approved product is a prescription drug, not an over-the-counter treatment.[1]
The product’s regulatory profile has four commercial implications:
- The active ingredient, acyclovir, is well established and inexpensive.
- The formulation and delivery system carry more strategic importance than the molecule.
- A generic applicant could potentially pursue an abbreviated new drug application if it can demonstrate pharmaceutical equivalence and bioequivalence.
- The product does not have the regulatory protection associated with a new molecular entity.
Sitavig is not a biologic, so biosimilar regulation does not apply. Any competitive copy would be evaluated as a generic drug or a formulation-specific equivalent, not as a biosimilar.
What is the Orange Book status of Sitavig?
The FDA Orange Book is the primary source for determining listed patents, exclusivity and therapeutic-equivalence status for an approved small-molecule product.[2]
Sitavig’s commercial protection is principally formulation-based. The relevant protection is expected to relate to:
- Mucoadhesive buccal delivery.
- Acyclovir particle or dosage-form composition.
- Residence of the tablet on the gingival or buccal surface.
- Dosing and administration at the prodromal stage.
- Manufacturing controls needed to produce a tablet with consistent adhesion and release.
The practical importance of any Orange Book listing depends on whether a listed patent remains unexpired and whether an ANDA applicant files a Paragraph IV certification.
What patents protect Sitavig?
Sitavig was developed around the Lauriad mucoadhesive delivery platform, originally associated with BioAlliance Pharma, later known as Onxeo. Public patent families associated with the product and platform have focused on oral mucoadhesive formulations rather than novel acyclovir chemistry.
| Protection category |
Commercial relevance |
| Mucoadhesive acyclovir composition |
Protects the physical dosage form |
| Buccal or gingival placement |
Limits copying of the administration route |
| Controlled local release |
Supports residence and exposure claims |
| Tablet manufacturing process |
Can complicate exact formulation replication |
| Method of treating herpes labialis |
May protect dosing at first symptoms, subject to claim scope |
| Platform patents |
May cover multiple active ingredients and products |
Patent term depends on the specific family, priority date, patent-term adjustment, terminal disclaimers and any patent-term extension. The acyclovir molecule itself is long off patent. Any remaining protection must therefore be assessed patent by patent rather than inferred from the product’s 2013 approval date.
How strong is the Sitavig patent estate?
The estate is commercially differentiated but not structurally strong by specialty-pharma standards.
Its strengths are:
- A defined delivery problem.
- A formulation that may be harder to duplicate than conventional oral acyclovir.
- Potential protection around adhesion, release and manufacturing.
- A product-specific clinical and regulatory record.
Its weaknesses are:
- No new molecular entity protection.
- A low-cost active ingredient.
- A small and episodic treatment market.
- Multiple alternative antivirals.
- Potential design-around options using different polymers, dosage forms or release profiles.
- Limited evidence of broad patent litigation or sustained patent-enforcement activity.
A generic applicant could challenge patents through Paragraph IV certification or develop a different buccal formulation that avoids asserted claims. The commercial risk would depend on whether the generic is therapeutically equivalent to Sitavig or instead competes through a separate 505(b)(2) pathway.
When does Sitavig lose exclusivity?
The key distinction is between FDA regulatory exclusivity and patent exclusivity.
The five-year new chemical entity exclusivity period does not apply because acyclovir was already approved. Sitavig may have received three-year clinical-investigation exclusivity for the new dosage form or indication, but that period would have expired years ago.[2]
The remaining protection is therefore patent-driven. A definitive generic-entry date requires confirmation of the current Orange Book listing and the expiration status of each enforceable patent family.
What generic entry risks exist for Sitavig?
Generic risk is moderate to high over the long term.
A potential ANDA challenger would evaluate:
- Whether Sitavig has active Orange Book-listed patents.
- Whether the reference product remains commercially available.
- Whether the formulation can be reproduced with equivalent adhesion and release.
- Whether the generic must demonstrate bioequivalence through pharmacokinetic, pharmacodynamic or clinical testing.
- Whether a Paragraph IV challenge would trigger a 30-month stay under the Hatch-Waxman framework.
- Whether a settlement agreement restricts launch timing.
For a small product, the cost of a complex bioequivalence program can deter entry. That deterrent is weaker when the product has a large market, high price or multiple approved manufacturers. Sitavig appears to have the opposite profile: a niche indication, low active-ingredient cost and limited sales visibility.
Has Sitavig faced Paragraph IV litigation or patent settlements?
No major, widely reported Paragraph IV litigation campaign involving Sitavig has emerged in the public record available through June 2024. No high-profile generic settlement has established a recognized authorized-generic or first-entry framework for the product.
The absence of public litigation does not prove that no ANDA challenge exists. It indicates that Sitavig has not generated the level of patent-dispute activity seen with high-revenue specialty medicines.
A future challenge would likely focus on formulation patents, obviousness of combining acyclovir with known mucoadhesive excipients, written-description support and enablement. Method-of-use claims could face additional scrutiny because early treatment of recurrent herpes labialis is a clinically conventional antiviral-use concept.
What is the commercial market for Sitavig?
Sitavig competes in the recurrent herpes labialis market, which includes prescription antivirals, OTC topical products and no-treatment behavior.
Competitive products
| Product |
Ingredient |
Route |
Commercial position |
| Sitavig |
Acyclovir |
Single-dose buccal tablet |
Differentiated adherence and delivery |
| Zovirax generic |
Acyclovir |
Repeated oral dosing |
Low-cost prescription alternative |
| Valtrex generic |
Valacyclovir |
Oral dosing |
Convenient systemic antiviral option |
| Famvir generic |
Famciclovir |
Oral dosing |
Alternative episodic antiviral |
| Abreva |
Docosanol |
Topical OTC |
Broad consumer recognition |
| OTC topical products |
Various |
Topical |
Low price and self-treatment |
Sitavig’s main competitive advantage is convenience at symptom onset. Its main disadvantage is that oral valacyclovir already offers a simple episodic regimen and is available generically.
What is Sitavig’s revenue exposure?
Publicly reliable, product-level Sitavig revenue data is limited. The product is not generally treated as a major revenue contributor within the global antiviral market.
Revenue exposure is likely concentrated in:
- The United States.
- Dermatology and primary-care prescribing.
- Patients who prefer a single local dose.
- Consumers with recurrent cold sores who seek prescription treatment.
- Specialty-pharmacy or direct-prescription channels, depending on current distribution.
The product’s revenue ceiling is limited by episodic use. Patients may experience several outbreaks per year, but each episode generally requires only one tablet. That reduces annual units per patient relative to repeated-dose oral therapy.
What is the Sitavig market projection?
A precise revenue forecast cannot be based on public clinical-trial data alone. A scenario approach is more appropriate.
| Scenario |
Market assumption |
Five-year commercial direction |
| Downside |
Distribution weakness, generic substitution and limited payer coverage |
Declining or minimal revenue |
| Base case |
Stable niche prescribing with modest adherence-driven demand |
Low single-digit growth or flat sales |
| Upside |
Improved availability, direct-to-consumer awareness and premium reimbursement |
Moderate growth from a small base |
The base case is more defensible than a high-growth forecast. Sitavig has an approved product and a differentiated formulation, but it lacks the characteristics that normally support rapid pharmaceutical expansion: a novel mechanism, broad chronic use, high disease severity, strong reimbursement leverage or a large protected population.
An upside case would require a commercial partner to improve physician education, prescription fulfillment and payer access. A new formulation or evidence package demonstrating advantages over oral valacyclovir could improve the position, but no such program is established in the public record through June 2024.
How does Sitavig compare with oral valacyclovir?
Oral valacyclovir has the stronger commercial position. It is systemically delivered, familiar to prescribers and widely available as a generic. Sitavig has a more specialized administration route and may improve adherence for patients who want one application at the first sign of an outbreak.
| Factor |
Sitavig |
Generic valacyclovir |
| Dose frequency |
Single buccal tablet |
Episodic oral regimen |
| Active ingredient |
Acyclovir |
Valacyclovir |
| Delivery |
Local buccal adhesion |
Systemic oral absorption |
| Generic pressure |
Formulation-specific |
Strong and established |
| Prescriber familiarity |
Lower |
High |
| Price flexibility |
Potentially higher |
Limited |
| Patent differentiation |
Delivery system |
Limited molecule protection |
| Market scale |
Niche |
Broad prescription use |
Sitavig can retain a niche if its convenience is valued enough to support a price premium. It is unlikely to displace generic valacyclovir across the broader recurrent-herpes market.
What manufacturing and intellectual-property barriers affect Sitavig?
Manufacturing barriers are higher than for standard acyclovir tablets because the product must achieve several performance attributes simultaneously:
- Consistent mucoadhesion.
- Reliable tablet placement and retention.
- Controlled release at the gingival site.
- Acceptable taste and mouthfeel.
- Mechanical stability during packaging and transport.
- Consistent assay and content uniformity.
- Reproducible dissolution and adhesion testing.
These requirements can deter casual copying. They do not eliminate generic risk because a well-funded applicant can develop an equivalent or design-around formulation.
Geographic protection also varies. U.S. patent rights, European patent rights and rights in other jurisdictions expire independently and may have different validation, opposition and enforcement histories. The product’s commercial value is therefore jurisdiction-specific.
What licensing deals affect Sitavig?
Sitavig originated from the Lauriad mucoadhesive technology platform associated with BioAlliance Pharma. Product commercialization and regional rights have been affected by corporate restructuring and licensing arrangements involving BioAlliance and its successor Onxeo.[3]
The commercial importance of any license depends on:
- Territory.
- Royalty rate.
- Minimum sales obligations.
- Manufacturing rights.
- Patent-prosecution control.
- Termination provisions.
- Rights after loss of regulatory approval or market withdrawal.
Sitavig’s license structure should be reviewed alongside current distribution agreements because patent ownership and commercial availability may not reside with the same entity.
What generic launch scenarios are most likely?
The most likely launch paths are:
- No immediate generic launch. Limited market size may not justify development expenditure.
- Formulation-specific ANDA. A challenger establishes equivalence to the approved buccal tablet and challenges remaining listed patents.
- 505(b)(2) alternative. A company develops a different mucoadhesive acyclovir formulation with partial reliance on Sitavig’s safety and efficacy data.
- Commercial erosion without a formal generic. Physicians and patients substitute generic oral valacyclovir because of price or availability.
The fourth scenario can reduce Sitavig sales even without patent litigation. For a niche product, access and prescribing behavior may matter more than the formal patent expiry date.
Key Takeaways
- Sitavig is a 50 mg single-dose acyclovir buccal tablet approved by the FDA in 2013 for recurrent herpes labialis.
- Its clinical development is complete; no major active late-stage program was evident through June 2024.
- The product’s differentiation comes from mucoadhesion and convenience, not a novel antiviral mechanism.
- NCE exclusivity does not apply because acyclovir was previously approved.
- Remaining protection is formulation-, method-of-use- and manufacturing-patent dependent.
- No major public Paragraph IV litigation or settlement has defined Sitavig’s generic-entry outlook through June 2024.
- Generic valacyclovir is the principal commercial competitor.
- The base-case outlook is a stable or declining niche product unless distribution, reimbursement or patient adherence improves.
- Sitavig is not subject to biosimilar competition because it is a small-molecule drug.
- Patent and commercial risk must be assessed separately by jurisdiction and current Orange Book status.
FAQs About Sitavig Patents, Clinical Trials and Market Entry
Is Sitavig the same drug as Zovirax?
Both contain acyclovir, but Sitavig is a single-dose mucoadhesive buccal tablet. Zovirax is associated with conventional acyclovir formulations, including oral and topical products.
Can a patient take Sitavig with oral valacyclovir?
Sitavig labeling does not establish routine combined use with oral valacyclovir. Treatment selection should follow the approved prescribing information and clinician direction.
Does Sitavig treat genital herpes?
No. The FDA-approved indication is recurrent herpes labialis in immunocompetent adults.
Is Sitavig available over the counter?
No. Sitavig is an FDA-approved prescription product. OTC cold-sore products such as docosanol occupy a separate commercial category.
What would make Sitavig commercially valuable to a licensing partner?
The strongest licensing drivers would be enforceable formulation patents, reliable U.S. supply, favorable reimbursement, a differentiated price-supported adherence benefit and evidence showing an advantage over generic oral valacyclovir.
References
- U.S. Food and Drug Administration. (2013). Sitavig (acyclovir) buccal tablet prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Onxeo S.A. (2014). Annual report and corporate information concerning Lauriad and Sitavig commercialization.
- ClinicalTrials.gov. (2024). Studies evaluating acyclovir mucoadhesive buccal tablet for recurrent herpes labialis. National Library of Medicine.
